Research Article
Preclinical Evaluation of [18F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic Transporters
Figure 2
(a) Time-activity profiles obtained from the images of the abdominal aorta of control, rifamycin SV-treated, and fusidate-treated rats. No statistical significance of rifamycin-SV and fusidate-treated rats compared to the control was found at any point (error bars omitted for clarity). (b) Time-activity profiles obtained from the images of the liver of control, rifamycin SV-treated, and fusidate-treated rats as mean ±1 s.d., . (c) Time-activity profiles for the bile, obtained from the images of the gastrointestinal region of control, rifamycin SV-treated, and fusidate-treated rats as mean ±1 s.d., . (d) Activity in the liver of control, rifamycin SV-treated, and fusidate-treated rats at 2 minutes postinjection determined noninvasively via PET imaging, as mean ±1 s.d., . Statistical significance of rifamycin-SV and fusidate-treated rats compared to the control was assessed by two-tailed t-test assuming equal variances, .
| (a) |
| (b) |
| (c) |
| (d) |